Nova Laboratories Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 9.82 Cr
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -4.97%
- Profit Growth 30.00%
- Ebitda 21.13%
- Net Worth 13.32%
- Total Assets 13.07%
About Nova Laboratories
Nova Laboratories Private Limited (NLPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 June 2017 (Seven years and seven months 28 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.82 Cr, as per Ministry of Corporate Affairs (MCA) records.
Irfan Dhorajiwala, Reshma Ahmed, Peter Franik, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304MH2017PTC296093
-
Company No.
296093
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Jun 2017
-
Date of AGM
01 Aug 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nova Laboratories?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Irfan Dhorajiwala
|
Director | 13-Jun-2017 | Current |
|
Reshma Ahmed
|
Director | 13-Jun-2017 | Current |
Peter Franik
|
Director | 06-Sep-2018 | Current |
Chen Zhanzhi
|
Director | 10-Oct-2019 | Current |
Financial Performance of Nova Laboratories.
Nova Laboratories Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 4.97% decrease. The company also saw a substantial improvement in profitability, with a 30% increase in profit. The company's net worth Soared by an impressive increase of 13.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nova Laboratories?
In 2022, Nova Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Thaiger Pharma Private LimitedIrfan Dhorajiwala is a mutual person
-
Thaiger Nutraceuticals Private LimitedIrfan Dhorajiwala, Reshma Ahmed and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nova Laboratories?
Unlock and access historical data on people associated with Nova Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nova Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nova Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.